Cell death in pancreatic cancer: from pathogenesis to therapy
Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …
[HTML][HTML] Targeting PI3K/AKT/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects
S Stanciu, F Ionita-Radu, C Stefani, D Miricescu… - International Journal of …, 2022 - mdpi.com
Although pancreatic cancer (PC) was considered in the past an orphan cancer type due to
its low incidence, it may become in the future one of the leading causes of cancer death …
its low incidence, it may become in the future one of the leading causes of cancer death …
[HTML][HTML] Liposome-based diagnostic and therapeutic applications for pancreatic cancer
Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …
Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade
VE Lander, JI Belle, NL Kingston, JM Herndon… - Cancer discovery, 2022 - AACR
The effects of radiotherapy (RT) on tumor immunity in pancreatic ductal adenocarcinoma
(PDAC) are not well understood. To better understand if RT can prime antigen-specific T-cell …
(PDAC) are not well understood. To better understand if RT can prime antigen-specific T-cell …
[HTML][HTML] GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
C Pecoraro, B Faggion, B Balboni, D Carbone… - Drug Resistance …, 2021 - Elsevier
Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …
[HTML][HTML] OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment
S Liu, F Li, Q Ma, M Du, H Wang, Y Zhu, L Deng… - Theranostics, 2023 - ncbi.nlm.nih.gov
Rationale: The resistance of pancreatic ductal adenocarcinoma (PDAC) to immunotherapies
is caused by the immunosuppressive tumor microenvironment (TME) and dense …
is caused by the immunosuppressive tumor microenvironment (TME) and dense …
[HTML][HTML] Gastrointestinal stromal tumors (GISTs): novel therapeutic strategies with immunotherapy and small molecules
C Vallilas, P Sarantis, A Kyriazoglou, E Koustas… - International Journal of …, 2021 - mdpi.com
Gastrointestinal stromal tumors (GISTs) are the most common types of malignant
mesenchymal tumors in the gastrointestinal tract, with an estimated incidence of 1.5/100.000 …
mesenchymal tumors in the gastrointestinal tract, with an estimated incidence of 1.5/100.000 …
[HTML][HTML] DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal …
AA Fitzgerald, S Wang, V Agarwal… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second
leading cause of cancer death in the USA by 2030. Immune checkpoint inhibitors fail to …
leading cause of cancer death in the USA by 2030. Immune checkpoint inhibitors fail to …
[HTML][HTML] Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
S Hao, S Xu, L Li, Y Li, M Zhao, J Chen, S Zhu, Y Xie… - BMC cancer, 2022 - Springer
Background: Antibodies and derivative drugs targeting immune checkpoints have been
approved for the treatment of several malignancies, but there are fewer responses in …
approved for the treatment of several malignancies, but there are fewer responses in …
[HTML][HTML] Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment
M Zuzčák, J Trnka - International Journal of Oncology, 2022 - spandidos-publications.com
Pancreatic cancer (PC) has one of the highest fatality rates and the currently available
therapeutic options are not sufficient to improve its overall poor prognosis. In addition to …
therapeutic options are not sufficient to improve its overall poor prognosis. In addition to …